Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2022; 19(02): 185-196
DOI: 10.1055/a-1816-1687
Übersicht

Update Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
Diana Lüftner
1   Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin
,
Florian Schütz
2   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf
,
Elmar Stickeler
3   Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen
,
Peter A. Fasching
4   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen
,
Wolfgang Janni
5   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm
,
Cornelia Kolberg-Liedtke
6   Department of Gynecology and Obstetrics, University Hospital Essen, Essen
7   palleos healthcare, Wiesbaden
8   Phaon Scientific, Wiesbaden
,
Hans-Christian Kolberg
9   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop
,
Christoph Thomssen
10   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale)
,
Volkmar Müller
11   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg
,
Tanja N. Fehm
12   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer
,
Erik Belleville
13   ClinSol GmbH & Co KG, Würzburg
,
Simon Bader
4   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen
,
Michael Untch
14   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Genecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin
,
Manfred Welslau
15   Onkologie Aschaffenburg, Aschaffenburg
,
Marc Thill
16   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main
,
Hans Tesch
17   Oncology Practice at Bethanien Hospital, Frankfurt am Main
,
Nina Ditsch
18   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg
,
Michael P. Lux
19   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn
,
Achim Wöckel
20   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg
,
Bahriye Aktas
21   Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Leipzig, Leipzig
,
Andreas Schneeweiss
22   National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg
,
Rachel Würstlein
23   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Andreas D. Hartkopf
24   Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Trotz der COVID-19-Pandemie und weitgehend virtueller Kongresse schreitet die Innovation in Bezug auf die Behandlung von Patientinnen mit Mammakarzinom mit ungebremster Geschwindigkeit fort. Dieser Übersichtsartikel fasst die aktuellen Entwicklungen zusammen. Die ersten Daten zum Gesamtüberleben für eine Therapie mit einem CDK4/6-Inhibitor in Kombination mit einem Aromatasehemmer bei nicht vorbehandelten, postmenopausalen Patientinnen in der ersten fortgeschrittenen Therapielinie wurden veröffentlicht. Ebenso zeigte eine Studie, die Trastuzumab-Deruxtecan mit Trastuzumab-Emtansin verglich, einen deutlichen Vorteil in Bezug auf das progressionsfreie Überleben. Die Kenntnisse über Biomarker, die eine Therapie mit einem Checkpoint-Inhibitor besonders effektiv machen, nehmen zu, und neue Substanzen wie die oralen selektiven Östrogenrezeptor-Destabilisatoren (SERDs) halten Einzug in die klinische Entwicklung und schließen die ersten Phase-III-Studien ab.

Abstract

Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumabemtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.

Schlüsselwörter

BRCA (breast cancer associated gene) - Genetik - Her‑2/neu (humaner epidermaler Wachstumsfaktor‑Rezeptor) - Hormonrezeptor - Mammakarzinom - Brust - Mamma

Key words

BRCA (breast cancer associated gene) - genetics - Her‑2/neu (human epidermal growth factor receptor) - hormonal receptor - breast cancer - breast


Publication History

Received: 06 December 2021

Accepted: 18 December 2021

Article published online:
10 June 2022

© 2022. This article was originally published by Thieme as Diana Lüftner et al., Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. Geburtsh Frauenheilk 2022; 82: 215–225 as an open access article under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. https://creativecommons.org/licenses/by-nc-nd/4.0/

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Jordan VC. Third annual William L. McGuire Memorial Lecture. “Studies on the estrogen receptor in breast cancer” – 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995; 36: 267-285
    CrossrefPubMedGoogle Scholar
  • 2 Drugs.com. Herceptin FDA Approval History. Online (Stand: 14.11.2021): https://www.drugs.com/history/herceptin.html#
    PubMedGoogle Scholar
  • 3 Hortobagyi GN, Stemmer SM, Burris III HA. et al. LBA17_PR – Overall survival (OS) results from the phase III MONALEESA‑2 (ML‑2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Ann Oncol 2021; 32 (Suppl. 05) S1283-S1346
    CrossrefPubMedGoogle Scholar
  • 4 Slamon DJ, Neven P, Chia S. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA‑3 trial: updated overall survival. Ann Oncol 2021; 32: 1015-1024
    CrossrefPubMedGoogle Scholar
  • 5 Tripathy D, Im SA, Colleoni M. et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA‑7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res 2021; 81 (04) PD2-04
    CrossrefPubMedGoogle Scholar
  • 6 Cristofanilli M, Rugo HS, Im SA. et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA‑3. J Clin Oncol 2021; 39 (15) 1000
    CrossrefPubMedGoogle Scholar
  • 7 Harbeck N, Rastogi P, Martin M. et al. Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. Ann Oncol 2021; 32: 1571-1581
    CrossrefPubMedGoogle Scholar
  • 8 OʼLeary B, Cutts RJ, Huang X. et al. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. J Natl Cancer Inst 2021; 113: 309-317
    CrossrefPubMedGoogle Scholar
  • 9 Andre F, Su F, Solovieff N. et al. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. J Clin Oncol 2020; 38 (15) 1009
    CrossrefPubMedGoogle Scholar
  • 10 Bidard FC, Callens C, Dalenc F. et al. Prognostic impact of ESR1 mutations in ER+HER2-MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA‑1 trial. J Clin Oncol 2020; 38 (15) 1010
    CrossrefPubMedGoogle Scholar
  • 11 European Medicines Agency. Summary of opinion (post authorisation): Faslodex (fulvestrant). Online (Stand: 16.10.2021): https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summarypositive-opinion-faslodex_en-0.pdf
    PubMedGoogle Scholar
  • 12 Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B. et al. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. Breast Cancer Res Treat 2019; 177: 115-125
    CrossrefPubMedGoogle Scholar
  • 13 Robertson JF. Fulvestrant (Faslodex) – how to make a good drug better. Oncologist 2007; 12: 774-784
    CrossrefPubMedGoogle Scholar
  • 14 Menari Group, Radius Health. Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer. Online (Stand: 22.10.2021): https://ir.radiuspharm.com/news-releases/news-release-details/menarini-groupand-radius-health-announce-positive-phase-3
    PubMedGoogle Scholar
  • 15 Snyder LB, Flanagan JJ, Qian Y. et al. Abstract 44: The discovery of ARV‑471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Res 2021; 81 (13) 44
    CrossrefPubMedGoogle Scholar
  • 16 ClinicalTrials.gov. Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA‑6) (SERENA‑6). Online (Stand: 24.10.2021): https://clinicaltrials.gov/ct2/show/NCT04964934
    PubMedGoogle Scholar
  • 17 André F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
    CrossrefPubMedGoogle Scholar
  • 18 ClinicalTrials.gov. Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK‑B5). Online (Stand: 24.10.2021): https://clinicaltrials.gov/ct2/show/NCT05038735
    PubMedGoogle Scholar
  • 19 Lux MP, Schneeweiss A, Hartkopf AD. et al. Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Frauenheilkd 2021; 81: 469-480
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 SOLTI Study Group. SOLTI launches HARMONIA, an international phase III study to identify the best therapeutic option for selected patients with aggressive HR+/HER2- advanced breast cancer. Online (Stand: 24.10.2021): https://www.gruposolti.org/ndp-harmonia-2021/?lang=en
    PubMedGoogle Scholar
  • 21 Katzorke N, Rack BK, Haeberle L. et al. Prognostic value of HER2 on breast cancer survival. J Clin Oncol 2013; 31 (15) 640
    CrossrefPubMedGoogle Scholar
  • 22 Taran FA, Fasching PA, Volz B. et al. Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry. Cancer Res 2018; 78: P5-21-09
    CrossrefPubMedGoogle Scholar
  • 23 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
    CrossrefPubMedGoogle Scholar
  • 24 Cortés J, Kim S, Chung W. et al. LBA1 – Trastuzumab deruxtecan (T‑DXd) vs. trastuzumab emtansine (T‑DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann Oncol 2021; 32 (Suppl. 05) S1283-S1346
    CrossrefPubMedGoogle Scholar
  • 25 Michel LL, Hartkopf AD, Fasching PA. et al. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T‑DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12: 3021
    CrossrefPubMedGoogle Scholar
  • 26 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
    CrossrefPubMedGoogle Scholar
  • 27 European Medicines Agency. Enhertu – Annex I. Summary of Product Characteristics. Online (Stand: 24.10.2021): https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-productinformation_en.pdf
    PubMedGoogle Scholar
  • 28 Saura Manich C, OʼShaughnessy J, Aftimos PF. et al. LBA15 – Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physicianʼs choice treatment in patients with pretreated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol 2021; 32 (Suppl. 05) S1283-S1346
    CrossrefPubMedGoogle Scholar
  • 29 Hanka LJ, Dietz A, Gerpheide SA. et al. CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot (Tokyo) 1978; 31: 1211-1217
    CrossrefPubMedGoogle Scholar
  • 30 Yuan Z, Huang JJ, Hua X. et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial. J Clin Oncol 2021; 39 (15) 1003
    CrossrefPubMedGoogle Scholar
  • 31 Rugo HS, Schmid P, Cescon DW. et al. Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE‑355 study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium, San Antonio, TX, USA. December 8-11 2020; DOI: 10.1158/1538-7445.SABCS20-GS3-01.
    CrossrefPubMedGoogle Scholar
  • 32 Schmid P, Rugo HS, Adams S. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 44-59
    CrossrefPubMedGoogle Scholar
  • 33 Miles D, Gligorov J, André F. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021; 32: 994-1004
    CrossrefPubMedGoogle Scholar
  • 34 Denkert C, von Minckwitz G, Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50
    CrossrefPubMedGoogle Scholar
  • 35 Würfel F, Erber R, Huebner H. et al. TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care (Basel) 2018; 13: 8-14
    CrossrefPubMedGoogle Scholar
  • 36 Fasching PA, Denkert C, Benz S. et al. Abstract PD5-08: Tumor immunecell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients – An analysis of the GeparSepto trial. Proceedings of the 2019 San Antonio Breast Cancer Symposium, San Antonio, TX, USA. December 10-14 2019; DOI: 10.1158/1538-7445. SABCS19-PD5-08.
    CrossrefPubMedGoogle Scholar
  • 37 Sinn BV, Loibl S, Hanusch CA. et al. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD‑L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clin Cancer Res 2021; 27: 2584-2591
    CrossrefPubMedGoogle Scholar
  • 38 Emens LA, Goldstein LD, Schmid P. et al. The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. J Clin Oncol 2021; 39 (15) 1006
    CrossrefPubMedGoogle Scholar
  • 39 Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541: 321-330
    CrossrefPubMedGoogle Scholar
  • 40 Burstein MD, Tsimelzon A, Poage GM. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015; 21: 1688-1698
    CrossrefPubMedGoogle Scholar
  • 41 Cortes J, Cescon DW, Rugo HS. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817-1828
    CrossrefPubMedGoogle Scholar
  • 42 Rugo HS, Cortés J, Cescon DW. et al. LBA16 – KEYNOTE‑355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs. placebo + chemotherapy for metastatic TNBC. Ann Oncol 2021; 32 (Suppl. 05) S1283-S1346
    CrossrefPubMedGoogle Scholar
  • 43 Turner NC, Ro J, André F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
    CrossrefPubMedGoogle Scholar
  • 44 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
    CrossrefPubMedGoogle Scholar
  • 45 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
    CrossrefPubMedGoogle Scholar
  • 46 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
    CrossrefPubMedGoogle Scholar
  • 47 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
    CrossrefPubMedGoogle Scholar
  • 48 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA‑7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-915
    CrossrefPubMedGoogle Scholar
  • 49 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
    CrossrefPubMedGoogle Scholar
  • 50 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA‑3. J Clin Oncol 2018; 36: 2465-2472
    CrossrefPubMedGoogle Scholar
  • 51 Sledge jr. GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-124
    CrossrefPubMedGoogle Scholar
  • 52 Sledge jr. GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
    CrossrefPubMedGoogle Scholar
  • 53 Jhaveri K, Juric D, Yap YS. et al. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021; 27: 5760-5770
    CrossrefPubMedGoogle Scholar
  • 54 Maglakelidze M, Bulat I, Ryspayeva D. et al. Rintodestrant (G1 T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results. J Clin Oncol 2021; 39 (15) 1063
    CrossrefPubMedGoogle Scholar
  • 55 Aftimos P, Neven P, Pegram M. et al. Abstract PS12-04: Rintodestrant (G1 T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection. Cancer Res 2021; 81 (04) PS12-04
    CrossrefPubMedGoogle Scholar
  • 56 Bardia A, Kaklamani V, Wilks S. et al. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol 2021; 39: 1360-1370
    CrossrefPubMedGoogle Scholar
  • 57 Hurvitz SA, Park YH, Bardia A. et al. LBA14 – Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs. anastrozole (A) + palbo in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. Ann Oncol 2021; 32 (Suppl. 05) S1283-S1346 DOI: 10.1016/j.annonc.2021.08.2086.
    CrossrefPubMedGoogle Scholar
  • 58 Liang J, Zbieg JR, Blake RA. et al. GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. J Med Chem 2021; 64: 11841-11856
    CrossrefPubMedGoogle Scholar
  • 59 Metcalfe C, Ingalla E, Blake RA. et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. Cancer Res 2019; 79 (04) P5-04-07
    CrossrefPubMedGoogle Scholar
  • 60 Chandarlapaty S, Linden HM, Neven P. et al. 264P – AMEERA‑1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC). Ann Oncol 2021; 32 (Suppl. 05) S457-S515
    PubMedGoogle Scholar
  • 61 Chandarlapaty S, Linden HM, Neven P. et al. AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). J Clin Oncol 2021; 39 (Suppl. 15) 1058-1058 DOI: 10.1200/JCO.2021.39.15_suppl.1058.
    CrossrefPubMedGoogle Scholar
  • 62 Shomali M, Sun F, Besret L. et al. Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD. Cancer Res 2021; 81: 739 DOI: 10.1158/1538-7445.AM2021-739.
    CrossrefPubMedGoogle Scholar
  • 63 Scott JS, Moss TA, Stokes S. et al. Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD). Cancer Res 2020; 80 (16) 5674
    CrossrefPubMedGoogle Scholar
  • 64 Bhagwat SV, Zhao B, Shen W. et al. Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Cancer Res 2021; 81 (13) 1236
    CrossrefPubMedGoogle Scholar
  • 65 Lim E, Beeram M, Prawira A. et al. Abstract OT‑09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer. Cancer Res 2021; 81 (04) OT‑09-03
    CrossrefPubMedGoogle Scholar
  • 66 Jhaveri KL, Lim E, Hamilton EP. et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. J Clin Oncol 2021; 39 (15) 1050
    CrossrefPubMedGoogle Scholar
  • 67 Samatar AA, Li J, Hegde S. et al. Abstract 4373: Discovery of ZN‑c5, a novel potent and oral selective estrogen receptor degrader. Cancer Res 2020; 80 (16) 4373
    CrossrefPubMedGoogle Scholar
  • 68 Osborne C, Richards DA, Wilks ST. et al. Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer. Cancer Res 2021; 81 (04) PS11-26
    CrossrefPubMedGoogle Scholar
  • 69 Hamilton EP, Wang JS, Pluard T. et al. Abstract PD8-06: Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium, San Antonio, TX, USA. December 8-11 2020; DOI: 10.1158/1538-7445.SABCS20-PD8-06.
    CrossrefPubMedGoogle Scholar